Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

163/433 Matches for
“prognosis”

“prognosis” Clear all
  1. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.

    Boursier J et al. · Aliment Pharmacol Ther · 2014 Match 100

    …test combination improves the liver-prognosis assessment in chronic hepatitis C (CHC…

    FibroTest HCV

  2. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 100

    …Patients' prognosis decreased as liver stiffness and FibroTest increased. In multivariate analysis…

    FibroTest HBV

  3. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

    Vergniol J et al. · Gastroenterology · 2011 Match 100

    …These tools might help physicians determine prognosis at earlier stages and discuss…

    FibroTest HCV HIV

  4. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

    Boursier J et al. · J Hepatol · 2016 Match 100

    …fibrosis with impaired liver-related prognosis. We aimed to compare blood fibrosis…

    FibroTest Metabolic

  5. Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.

    Rhodes FA et al. · J Gastroenterol Hepatol · 2021 Match 99

    …bias assessment using Quality in Prognosis Studies tool. ### Results Searches produced 25…

    FibroTest Alcohol

  6. Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.

    Park MS et al. · Liver Int · 2015 Match 99

    ### Background & Aims Liver stiffness (LS) measurement using transient elastography and the FibroTest…

    FibroTest HBV

  7. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review

    Moreno C et al. · J Hepatol · 2019 Match 99

    …diagnose more severe forms of ALD and to predict prognosis of patients.

    FibroTest Alcohol

  8. Liver fibrosis markers in alcoholic liver disease.

    Chrostek L et al. · World J Gastroenterol · 2014 Match 98

    …Staging of liver fibrosis is essential to define prognosis and management of…

    FibroTest Alcohol

  9. Noninvasive Assessment of Liver Fibrosis.

    Castera L · Dig Dis · 2015 Match 98

    ### Background The prognosis and management of chronic liver diseases greatly depend on…

    FibroTest HBV HCV

  10. FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.

    Munteanu M et al. · Liver Int · 2014 Match 98

    FibroTest HBV

  11. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 97

    …Early detection of liver disease may improve the prognosis of these patients.

    ActiTest FibroTest SteatoTest Metabolic

  12. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Match 97

    ### Background Medical comorbidities and functional status limitations are determinants of mortality in…

    FibroTest HCV

  13. Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013 Match 97

    FibroTest HBV

  14. Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.

    Elkrief L et al. · J Hepatol · 2023 Match 97

    ### Background & Aims In patients with compensated alcohol-related cirrhosis, reliable prognostic biomarkers…

    FibroTest Alcohol

  15. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

    Lombardi R et al. · World J Gastroenterol · 2015 Match 96

    Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…

    FibroTest Alcohol

  16. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Match 96

    …viral load testing accurately defined the prognosis and the inactive carrier status.

    ActiTest FibroTest HCV

  17. Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.

    Flores-Calderón J et al. · Ann Hepatol · 2012 Match 96

    …damage and to establish a prognosis. Utility of non-invasive markers of…

    FibroTest

  18. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 95

    ### Background Chronic HCV is one of the major causes of morbidity and…

    FibroTest HCV

  19. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.

    Bouayad A et al. · Pan Afr Med J · 2021 Match 95

    ### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…

    ActiTest FibroTest HCV

  20. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 95

    FibroTest Alcohol HBV HCV +3

  21. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 94

    ### Background In recent years noninvasive methods have been evaluated for the assessment…

    FibroTest SteatoTest Other

  22. Prognostic value of liver fibrosis biomarkers: a meta-analysis.

    Poynard T et al. · Gastroenterol Hepatol (N Y) · 2011 Match 94

    …a validated biomarker for the prognosis of patients with chronic liver disease.

    FibroTest Alcohol HBV HCV +3

  23. Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?

    Bush AM et al. · Aliment Pharmacol Ther · 2018 Match 94

    FibroTest Metabolic

  24. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

    Friedrich-Rust M et al. · BMC Gastroenterol · 2010 Match 93

    ### Background FibroTest (FT) is the most frequently used serum fibrosis marker and…

    FibroTest HBV HCV Other

  25. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

    Grigorescu M et al. · J Gastrointestin Liver Dis · 2007 Match 93

    ### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…

    FibroTest HCV

  26. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.

    Sagrini E et al. · Eur J Gastroenterol Hepatol · 2013 Match 93

    ### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…

    FibroTest HCV

  27. Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.

    Trnačević E et al. · Med Glas (Zenica) · 2021 Match 93

    Aim To assess concordance of eight frequently used serology-based scoring indices…

    FibroTest HCV

  28. [Prognosis assessment of alcoholic liver disease: how and why?].

    Trabut JB et al. · Presse Med · 2014 Match 92

    Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…

    FibroTest Alcohol

  29. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 92

    FibroTest Alcohol

  30. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Hepatology · 2009 Match 92

    ### Unlabelled The staging of liver fibrosis is pivotal for defining the prognosis

    FibroTest HCV

  31. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.

    Fierbinteanu-Braticevici C et al. · World J Gastroenterol · 2009 Match 91

    ### Aim To investigate the diagnostic accuracy of acoustic radiation force impulse (ARFI…

    FibroTest HCV

  32. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.

    Boursier J et al. · Clin Gastroenterol Hepatol · 2023 Match 91

    ### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…

    FibroTest Metabolic

  33. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 91

    ActiTest FibroTest HBV

  34. Non-invasive diagnosis and follow-up of portal hypertension.

    Thabut D et al. · Clin Res Hepatol Gastroenterol · 2022 Match 90

    Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis…

    FibroTest Alcohol HBV HCV +1

  35. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015 Match 90

    ### Background The diagnosis of alcoholic liver diseases is based on the history…

    ActiTest AshTest FibroTest NashTest +2

  36. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 90

    ### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…

    FibroTest COVID

  37. Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

    Tran A et al. · Clin Res Hepatol Gastroenterol · 2022 Match 89

    Hepatitis C virus (HCV) infection is a major cause of chronic liver…

    FibroTest HCV

  38. Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.

    Rudler M et al. · PLoS One · 2015 Match 89

    ### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…

    AshTest Alcohol

  39. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication

    Naveau S et al. · Hepatology · 2009 Match 89

    FibroTest has been validated as a biomarker of fibrosis in patients with…

    ActiTest AshTest FibroTest Alcohol

  40. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

    Stibbe KJ et al. · Scand J Gastroenterol · 2011 Match 89

    …Fibrosis assessment is essential to establish prognosis and treatment indication. We compared…

    FibroTest HBV HCV

  41. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

    Sebastiani G et al. · Can J Gastroenterol Hepatol · 2014 Match 88

    ### Objective To determine practices among physicians in Canada for the assessment of…

    FibroTest Alcohol HBV HCV +3

  42. [The prediction and validation of liver fibrosis by a noninvasive model and validation in patients with chronic hepatitis B].

    Liu WP et al. · Zhonghua Nei Ke Za Zhi · 2008 Match 88

    ### Objective To develop a simple model for the noninvasive diagnosis of liver…

    FibroTest HBV

  43. The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).

    Cylwik B et al. · J Clin Med · 2023 Match 88

    The aim of this study was to evaluate the diagnostic usefulness of…

    FibroTest Other

  44. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

    Morra R et al. · Hepatology · 2008 Match 87

    FibroTest Alcohol HBV HCV

  45. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.

    Said Y et al. · Tunis Med · 2010 Match 87

    ### Aim To assess the diagnostic value of Fibrotest in comparison with liver…

    FibroTest HCV

  46. Glycogenic hepatopathy.

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 87

    ### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…

    FibroTest Metabolic

  47. Hepatitis B: are non-invasive markers of liver fibrosis reliable?

    Castera L · Liver Int · 2014 Match 86

    Liver biopsy, which was traditionally considered to be the gold standard for…

    FibroTest HBV HCV

  48. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 86

    The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…

    ActiTest FibroTest NashTest SteatoTest +1

  49. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.

    Park MS et al. · PLoS One · 2013 Match 86

    ### Background And Aims The FibroTest (FT) demonstrated excellent diagnostic performance in the…

    FibroTest HBV

  50. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.

    Salkic NN et al. · Am J Gastroenterol · 2014 Match 85

    …most important factors in determining prognosis and the need for active treatment…

    FibroTest HBV

  51. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.

    Zarski JP et al. · PLoS One · 2013 Match 85

    ### Background And Aims We aimed to determine the best algorithms for the…

    FibroTest HCV

  52. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.

    Vallet-Pichard A et al. · Hepatology · 2006 Match 85

    FibroTest HCV

  53. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 85

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  54. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 84

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest

  55. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 84

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  56. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 84

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  57. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.

    Parikh P et al. · Ann Transl Med · 2017 Match 83

    Chronic hepatitis B virus (HBV) infection is a major cause of liver…

    FibroTest HBV

  58. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

    Sebastiani G et al. · World J Gastroenterol · 2007 Match 83

    ### Aim To assess the performance of several non-invasive markers and of…

    FibroTest HBV

  59. Non-invasive assessment of liver fibrosis: are we ready?

    Castera L et al. · Lancet · 2010 Match 83

    FibroTest Alcohol HBV HCV +1

  60. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.

    Naveau S et al. · Clin Gastroenterol Hepatol · 2005 Match 82

    ### Background & Aims The aim of this study was to determine the diagnostic…

    FibroTest Alcohol

  61. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 82

    **Background/Objectives**: Prior research has identified a significant association between heart disease…

    FibroTest Metabolic

  62. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.

    Friedrich-Rust M et al. · Ultraschall Med · 2009 Match 82

    ### Purpose Transient elastography (FibroScan, [TE]) and serum fibrosis markers such as the…

    FibroTest Alcohol HBV HCV +2

  63. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 81

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  64. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.

    Poynard T · J Hepatol · 2011 Match 81

    ActiTest AshTest FibroTest NashTest +7

  65. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.

    Preda CM et al. · Liver Int · 2018 Match 81

    ### Background Direct antiviral agents (DAA) showed very good results in terms of…

    FibroTest HCV

  66. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

    Munteanu M et al. · J Hepatol · 2011 Match 81

    FibroTest HBV HCV HIV

  67. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009 Match 80

    FibroTest HCV

  68. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 80

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  69. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 80

    ### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…

    FibroTest HCV

  70. Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.

    Voican CS et al. · Liver Int · 2017 Match 79

    ### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…

    FibroTest Alcohol

  71. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2018 Match 79

    ### Background Although the FibroTest has been validated as a biomarker to determine…

    FibroTest Alcohol HBV HCV +1

  72. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.

    Boursier J et al. · Am J Gastroenterol · 2011 Match 79

    ### Objectives Precise evaluation of the level of liver fibrosis is recommended in…

    FibroTest HCV

  73. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 78

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  74. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication

    Poynard T et al. · J Viral Hepat · 2009 Match 78

    The aim was to assess the utility of FibroTest-ActiTest (FT-AT…

    ActiTest FibroTest HBV

  75. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 78

    FibroTest HBV

  76. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 77

    …chosen and to predict the prognosis of patients with CHB. Liver biopsy…

    FibroTest HBV

  77. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.

    Cassinotto C et al. · Radiology · 2013 Match 77

    ### Purpose To compare the diagnostic performance of acoustic radiation force impulse (ARFI…

    FibroTest Alcohol HBV HCV +2

  78. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.

    Bourliere M et al. · J Viral Hepat · 2006 Match 77

    …70-0.82); for cirrhosis prognosis, AUCs of FT and APRI were…

    FibroTest HCV

  79. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.

    Thabut D et al. · J Hepatol · 2006 Match 77

    ### Background/Aims The aim was to identify a panel of biomarkers (AshTest…

    AshTest Alcohol

  80. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 76

    ### Introduction A prognostic model to predict liver severity in people with metabolic…

    FibroTest Metabolic

  81. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 76

    ### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…

    FibroTest SteatoTest Metabolic

  82. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 76

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  83. Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

    Poynard T et al. · BMJ Open · 2015 Match 75

    ### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…

    ActiTest FibroTest Alcohol HBV +3

  84. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 75

    FibroTest SteatoTest Metabolic

  85. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 75

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  86. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 74

    In the current era of therapy with direct-acting antiviral (DAAs) drugs…

    FibroTest HCV

  87. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

    Stasi C et al. · World J Gastroenterol · 2016 Match 74

    The assessment of the fibrotic evolution of chronic hepatitis has always been…

    FibroTest HCV

  88. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.

    Schmid P et al. · PLoS One · 2015 Match 74

    ### Objectives To evaluate the diagnostic performance of seven non-invasive tests (NITs…

    FibroTest HCV HIV

  89. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 74

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  90. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005 Match 73

    ActiTest FibroTest Alcohol HBV +3

  91. FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

    Poynard T et al. · J Hepatol · 2011 Match 73

    ### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…

    FibroTest HCV

  92. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

    Morali G et al. · Isr Med Assoc J · 2007 Match 73

    ### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…

    ActiTest FibroTest Alcohol HBV +1

  93. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.

    Rossi E et al. · Clin Chem · 2003 Match 72

    ### Background Determining the stage of fibrosis by liver biopsy is important in…

    FibroTest HCV

  94. American Association for the Study of the Liver

    Match 72

    FibroTest HCV

  95. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

    Bedossa P et al. · Hepatology · 1996 Match 72

    Histological activity reflects the global assessment of basic necroinflammatory lesions and is…

    HCV

  96. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 71

    ActiTest FibroTest HCV

  97. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 71

    ### Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as…

    FibroTest HCV

  98. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2011 Match 71

    ### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…

    FibroTest HBV HCV HIV +1

  99. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 70

    …to enable the prediction of prognosis and inform treatment decisions. However, as…

    FibroTest Alcohol

  100. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 70

    ### Background Since 1920, a decrease in serum cholesterol has been identified as…

    FibroTest COVID

  101. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Match 70

    ### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…

    FibroTest HCV

  102. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation.

    Chen J et al. · J Clin Lab Anal · 2013 Match 70

    ### Background Noninvasive laboratory tests have been widely used in the diagnosis of…

    FibroTest HBV

  103. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 69

    ### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…

    FibroTest Metabolic

  104. Effective use of FibroTest to generate decision trees in hepatitis C.

    Lau-Corona D et al. · World J Gastroenterol · 2009 Match 69

    ### Aim To assess the usefulness of FibroTest to forecast scores by constructing…

    FibroTest HCV

  105. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 69

    Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…

    FibroTest NashTest SteatoTest Metabolic

  106. Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.

    Kucharska M et al. · Adv Clin Exp Med · 2015 Match 68

    Haemophilia is an entity, wherein the HCV infection rate is greater than…

    FibroTest HCV

  107. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.

    Crisan D et al. · Indian J Med Res · 2017 Match 68

    ### Background & Objectives One of the multiple factors contributing to virological response in…

    ActiTest FibroTest SteatoTest HCV

  108. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.

    Sebastiani G et al. · J Viral Hepat · 2008 Match 68

    In chronic hepatitis C, biopsy is the gold standard for assessment of…

    FibroTest HCV

  109. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.

    Canbakan M et al. · Nephron Clin Pract · 2011 Match 67

    ### Background Liver biopsy is an imperfect gold standard for assessing the disease…

    FibroTest HCV

  110. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.

    Sebastiani G et al. · J Hepatol · 2006 Match 67

    ### Background/Aims In chronic hepatitis C, biopsy is the gold standard for…

    FibroTest HCV

  111. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.

    Fernandez M et al. · Eur J Gastroenterol Hepatol · 2015 Match 67

    ### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…

    FibroTest Alcohol

  112. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 66

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver…

    FibroTest Other

  113. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

    Castéra L et al. · Gastroenterology · 2005 Match 66

    ### Background And Aims Transient elastography (FibroScan; Echosens, Paris, France) is a novel…

    FibroTest HCV

  114. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.

    Patel K et al. · Aliment Pharmacol Ther · 2016 Match 66

    ### Background Assessment of fibrosis progression in chronic liver disease relies upon non…

  115. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 66

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  116. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 65

    ### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…

    FibroTest Metabolic

  117. Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.

    Chrostek L et al. · Biomed Res Int · 2019 Match 65

    The aim of this study was to evaluate the diagnostic values of…

    FibroTest Alcohol

  118. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.

    Köksal İ et al. · Turk J Gastroenterol · 2018 Match 65

    ### Background/Aims The hepatitis C virus (HCV) infection is important cause of…

    FibroTest HCV

  119. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.

    Maor Y et al. · Haemophilia · 2007 Match 64

    Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…

    FibroTest HCV

  120. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.

    Anastasiou J et al. · Eur J Gastroenterol Hepatol · 2010 Match 64

    ### Background The efficiency of transient elastography for the assessment of liver fibrosis…

    ActiTest FibroTest Alcohol HBV +3

  121. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.

    Chou R et al. · Ann Intern Med · 2013 Match 64

    ### Background Many blood tests have been proposed as alternatives to liver biopsy…

    FibroTest HCV

  122. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

    Myers RP et al. · J Hepatol · 2003 Match 63

    ### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…

    ActiTest FibroTest HBV

  123. Altered serum N-glycomics in chronic hepatitis B patients.

    Gui HL et al. · Liver Int · 2010 Match 63

    ### Background We previously reported on serum N-glycans as markers for the…

    FibroTest HBV

  124. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Match 63

    ### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…

    FibroTest SteatoTest Other

  125. Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

    Sadler MD et al. · Can J Gastroenterol Hepatol · 2015 Match 62

    ### Background Liver disease is the third leading cause of mortality in patients…

    FibroTest Other

  126. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

    Boursier J et al. · Hepatology · 2012 Match 62

    ### Unlabelled The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm…

    FibroTest HCV

  127. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 62

    ### Background And Aim One of the unmet needs in subjects with metabolic…

    ActiTest FibroTest NashTest NashTest-2 +3

  128. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.

    Więcek S et al. · Mediators Inflamm · 2020 Match 62

    Changes in the liver and bile ducts observed in patients diagnosed with…

    ActiTest FibroTest Other

  129. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

    Thabut D et al. · Am J Gastroenterol · 2006 Match 61

    ### Background Few data are available on chronic hepatitis C (CHC) in elderly…

    FibroTest HCV

  130. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

    Yakoob R et al. · Ann Gastroenterol · 2015 Match 61

    ### Background The aim of this study was to compare noninvasive biomarkers, FibroTest…

    ActiTest FibroTest HCV

  131. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.

    Naveau S et al. · Eur J Gastroenterol Hepatol · 2014 Match 61

    ### Background And Aims The PGAA index was one of the first composite…

    FibroTest Alcohol

  132. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.

    Bottero J et al. · J Hepatol · 2009 Match 60

    ### Background/Aims The aim of this study was to compare the performance…

    FibroTest HBV HIV

  133. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 60

    ### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…

    FibroTest HIV

  134. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Match 60

    ### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…

    FibroTest HCV

  135. Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.

    Poynard T et al. · PLoS One · 2016 Match 59

    ### Background And Aims Real-time shear wave elastography (2D-SWE) is a…

    ActiTest FibroTest SteatoTest Alcohol +3

  136. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

    Patel K et al. · World J Gastroenterol · 2011 Match 59

    ### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…

    FibroTest HCV

  137. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 59

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  138. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.

    Ratziu V et al. · J Hepatol · 2011 Match 58

    ### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…

    FibroTest Metabolic

  139. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 58

    In patients with non-alcoholic fatty liver disease (NAFLD) with or without…

    FibroTest Metabolic

  140. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 58

    ### Background Studies have demonstrated that coronary artery calcification on one hand and…

    ActiTest FibroTest NashTest SteatoTest +1

  141. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.

    Boursier J et al. · BMC Gastroenterol · 2011 Match 58

    ### Background Non-invasive tests have been constructed and evaluated mainly for binary…

    FibroTest HCV

  142. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 57

    As of 2016, there is no evidence-based pathway to stratify the…

    FibroTest Other

  143. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication

    Shiha G et al. · Hepatol Int · 2009 Match 57

    Liver fibrosis is a common pathway leading to cirrhosis, which is the…

    FibroTest SteatoTest HBV HCV +1

  144. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 57

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  145. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 56

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  146. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 56

    ### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…

    FibroTest Alcohol HBV HCV +3

  147. Assessment of liver fibrosis: noninvasive means.

    Poynard T et al. · Saudi J Gastroenterol · 2008 Match 56

    Liver biopsy, owing to its limitations and risks, is an imperfect gold…

    FibroTest Alcohol HBV HCV +3

  148. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.

    Sebastiani G et al. · Aliment Pharmacol Ther · 2012 Match 55

    ### Background Preliminary data suggest that performance of non-invasive markers for liver…

    FibroTest HCV

  149. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 55

    ### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…

    LCR1 LCR2 HCV

  150. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 55

    ### Background Noninvasive tests are crucial for the management and follow-up of…

    ActiTest FibroTest AIH

  151. External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.

    Poynard T et al. · Gastro Hep Adv · 2022 Match 54

    ### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…

    FibroTest LCR1 LCR2 Surveillance-FibroTest +1

  152. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 54

    A common clinical concern in patients with NAFLD is whether they have…

    ActiTest FibroTest NashTest SteatoTest +1

  153. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 54

    ### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…

    ActiTest FibroTest NashTest SteatoTest +1

  154. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 54

    Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…

    FibroTest Metabolic

  155. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.

    Houot M et al. · Aliment Pharmacol Ther · 2016 Match 53

    ### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…

    FibroTest HBV HCV

  156. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 53

    ### Background Biopsy is the usual gold standard for liver steatosis assessment. The…

    SteatoTest Alcohol HBV HCV +1

  157. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 53

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  158. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 52

    With great advancements in the therapeutic modalities used for the treatment of…

    FibroTest Alcohol HBV HCV +3

  159. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 52

    Liver cirrhosis in Mexico is one of the most important causes of…

    FibroTest HCV

  160. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 52

    ActiTest FibroTest HCV

  161. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 51

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  162. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 51

    ActiTest FibroTest HBV

  163. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.